- Report
- January 2021
- 245 Pages
Global
From €3140EUR$3,600USD£2,737GBP
- Report
- July 2024
- 100 Pages
Global
From €3271EUR$3,750USD£2,851GBP
- Report
- July 2024
- 150 Pages
Global
From €3271EUR$3,750USD£2,851GBP
- Report
- July 2024
- 100 Pages
Global
From €3271EUR$3,750USD£2,851GBP
- Report
- July 2024
- 100 Pages
Global
From €3271EUR$3,750USD£2,851GBP
- Report
- July 2024
- 150 Pages
Global
From €3271EUR$3,750USD£2,851GBP
- Report
- February 2024
- 119 Pages
Global
From €6934EUR$7,950USD£6,043GBP
- Report
- May 2024
- 124 Pages
Global
From €2584EUR$2,963USD£2,252GBP
€3445EUR$3,950USD£3,003GBP
- Report
- May 2024
- 100 Pages
Global
From €2584EUR$2,963USD£2,252GBP
€3445EUR$3,950USD£3,003GBP
- Report
- July 2023
- 110 Pages
Global
From €3925EUR$4,500USD£3,421GBP
- Report
- December 2022
- 119 Pages
Global
From €3925EUR$4,500USD£3,421GBP
- Report
- October 2024
- 250 Pages
Global
From €4317EUR$4,949USD£3,762GBP
- Report
- November 2023
- 160 Pages
Global
From €3139EUR$3,599USD£2,736GBP
- Report
- May 2023
- 140 Pages
Global
From €4317EUR$4,949USD£3,762GBP
- Report
- May 2024
- 210 Pages
Global
From €3881EUR$4,450USD£3,383GBP
- Report
- February 2024
- 80 Pages
From €3009EUR$3,450USD£2,623GBP
- Report
- February 2024
- 79 Pages
North America
From €3009EUR$3,450USD£2,623GBP
- Report
- February 2024
- 83 Pages
Middle East, Africa
From €3009EUR$3,450USD£2,623GBP
- Report
- February 2024
- 95 Pages
Europe
From €3009EUR$3,450USD£2,623GBP
- Report
- February 2024
- 91 Pages
Asia Pacific
From €3009EUR$3,450USD£2,623GBP

Age-related Macular Degeneration (AMD) is a degenerative eye condition that affects the macula, the part of the eye responsible for central vision. It is the leading cause of vision loss in people over the age of 50. AMD is a major concern for the optical industry, as it can lead to severe vision impairment and blindness.
Optical companies are developing treatments and technologies to help diagnose and manage AMD. These include optical coherence tomography (OCT) imaging, which can detect early signs of AMD, and anti-VEGF drugs, which can slow the progression of the disease. Additionally, companies are developing new lenses and other optical devices to help improve vision in those with AMD.
Companies in the AMD market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more